Press Releases

Awards support development of novel targeted agent, understanding immune system’s role in cancer
Tuesday, September 19, 2017

Researchers at Roswell Park Cancer Institute recently received more than $6.8 million in grant awards to support six specific projects aimed at improving supportive care and developing new immunotherapy and targeted therapy treatment approaches.

One of the most efficient resources of its kind, Quitline is a key component of state’s efforts to advance public health
Friday, September 15, 2017

BUFFALO, N.Y. — For many smokers fighting tobacco addiction, an encouraging voice on the other end of the phone is the difference-maker that helps them to quit smoking for good — often after a series of unsuccessful quit attempts. For the last 17 years, New Yorkers have relied on support available on demand, when they needed it most, at the other end of a phone connection or through a wealth of online cessation resources.

Becker’s Hospital Review looks at data from many sources in compiling annual list
Friday, September 15, 2017

Roswell Park Cancer Institute has once again been named to Becker’s Hospital Review’s 100 Hospitals and Health Systems with Great Oncology Programs, an annual list of centers that are national leaders in patient care, cancer outcomes and research.

Thursday, September 14, 2017

An unprecedented network of centers collaborating to share information and translate these pooled resources into personalized treatments for cancer patients has expanded to 16 institutions with the addition of Roswell Park Cancer Institute as a member.

Tuesday, September 12, 2017

New research led by a team from Roswell Park Cancer Institute and published in the journal Nature Methods reports the development of genetically encoded GTP sensors that can rapidly detect changes in GTP levels in living cells.

Thursday, September 7, 2017

Chemotherapy-induced peripheral neuropathy, or CIPN, is a common side effect of cancer treatment that causes shooting or burning pain, numbness, tingling and cold sensitivity of the hands and feet for many cancer patients.

Wednesday, August 30, 2017

While the development of therapies designed to block “checkpoints” within the immune system has been one of the most exciting and noteworthy advances in cancer research in recent years, it’s also been one of the most puzzling, leaving researchers to ask: Why don’t these new therapies work for more patients, and why is their efficacy in controlling cancerous tumors often short-lived? A research team from Roswell Park Cancer Institute has shown that at least one answer — and an excellent opportunity for unleashing the full potential of these promising immunotherapies — may lie in the body’s “fight or flight” reaction to stressors and in drugs already widely used to control and temporarily disable this stress response.

Tuesday, August 15, 2017

Carly’s Club, an organization that raises funds for pediatric cancer research and family support programs at Roswell Park Cancer Institute, announced today that it has rebranded as the Courage of Carly Fund. 

Tuesday, August 15, 2017

The first study to report that overall survival was extended for patients receiving lenalidomide as maintenance treatment for multiple myeloma has been completed, with the team’s findings now published online ahead of print in the Journal of Clinical Oncology.

Tuesday, August 8, 2017

Roswell Park Cancer Institute has been named a 2017–18 Best Hospital for cancer by U.S. News & World Report. The Buffalo, N.Y., comprehensive cancer center was ranked by the news outlet as 33rd among nearly 900 cancer hospitals reviewed nationwide, and was also recognized as high-performing within two other categories: urology and lung cancer surgery.

Monday, August 7, 2017

The U.S. Food and Drug Administration has awarded orphan drug status to a promising immunotherapy vaccine developed at Roswell Park Cancer Institute. The FDA notified MimiVax LLC, a Roswell Park spinoff company, on Aug. 3 that its application for orphan status for SurVaxM as treatment for glioblastoma, a type of brain cancer, had been approved.

Saturday, August 5, 2017

Today, 101 cyclists crossed the Niagara Falls finish line to complete the Empire State Ride (ESR), a seven-day, 546-mile adventure across New York State to end cancer. To participate, individuals from as far as California and the Virgin Islands raised more than $500,000 to support cancer research at Roswell Park Cancer Institute.